Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885963 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00885963: Clinical Trial Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
NCT00885963 is a Phase 2 study that was terminated before completion, run by Cyclacel Pharmaceuticals. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00885963, a Phase 2 study, was terminated before completion, sponsored by Cyclacel Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).
Primary Outcome
complete response or partial response and stable disease
Interventions
- DRUG sapacitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-12-01 |
| Est. Completion | 2013-12-23 |
| Phase | Phase 2 |
Why NCT00885963 stopped before completion
NCT00885963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which sapacitabine is the first listed.
NCT00885963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00885963 about?
NCT00885963 is a clinical study titled "A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer". A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00885963?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2008-12-01. Estimated completion is 2013-12-23.
What interventions are being tested in trial NCT00885963?
The interventions under investigation include: sapacitabine (DRUG).
Who is sponsoring clinical trial NCT00885963?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00885963's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI